Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial.
about
Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials.Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.When to transplant MDS, and what to do when transplant fails.Optimal therapy for adult patients with acute myeloid leukemia in first complete remission.Reduced-intensity conditioned allogeneic SCT in adults with AML.Invariant natural killer T cells in hematopoietic stem cell transplantation: killer choice for natural suppression.Life after transplant: are we becoming high maintenance in AML?PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.Lenalidomide-induced graft-vs.-Leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplant.Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia.Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients.
P2860
Q30249246-F84DF2DC-37F9-4DE0-AA46-3A042B2993C0Q34342944-CC5B7306-88CA-47B2-BF8F-E6970764E2F2Q37216476-4A107698-2955-4DF5-A7F3-C9FB149DD3C5Q38148983-1DFA7BF4-7CD3-4D65-90FA-E7F239C94366Q38208953-B499771B-247D-4BBF-AEB7-9B46C3ACBAD5Q38366632-139234BE-84CF-47B0-8E19-E4184C89417AQ38734173-6DBC4D09-CB52-4100-B313-8AE06D46524CQ38801124-B6EE8683-38BD-4BA5-ABEE-4AF63EF1B5A0Q40216708-939A78B1-CE73-497A-A547-EE01F2BA0155Q40493612-CCD9DB89-02EA-475F-8D9B-129D428E27E4Q41509184-E6B9DEBB-B8FA-4B5B-98D1-7B743BBF3F78Q50853922-B0518BD4-4EBC-4D13-BA2B-14F3F7913B6E
P2860
Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Lenalidomide maintenance after ...... acute myeloid leukemia and del
@nl
Lenalidomide maintenance after ...... esults of the LENAMAINT trial.
@en
type
label
Lenalidomide maintenance after ...... acute myeloid leukemia and del
@nl
Lenalidomide maintenance after ...... esults of the LENAMAINT trial.
@en
prefLabel
Lenalidomide maintenance after ...... acute myeloid leukemia and del
@nl
Lenalidomide maintenance after ...... esults of the LENAMAINT trial.
@en
P2093
P2860
P50
P1433
P1476
Lenalidomide maintenance after ...... esults of the LENAMAINT trial.
@en
P2093
Brigitte Mohr
Christian Unzicker
Dietrich Beelen
Eva Mischak-Weissinger
German MDS and Cooperative Transplant Study Group (GCTSG)
Guido Kobbe
Jochen Greiner
Jürgen Finke
Katja Sockel
Martin Bornhaeuser
P2860
P356
10.3324/HAEMATOL.2012.067629
P577
2012-09-01T00:00:00Z